May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Regulation of PAI-1 Protein in Human Trabecular Meshwork Cells
Author Affiliations & Notes
  • D. L. Fleenor
    Glaucoma Research, Alcon Research Ltd, Fort Worth, Texas
  • I.-H. Pang
    Glaucoma Research, Alcon Research Ltd, Fort Worth, Texas
  • A. F. Clark
    Glaucoma Research, Alcon Research Ltd, Fort Worth, Texas
  • Footnotes
    Commercial Relationships  D.L. Fleenor, Alcon Research Ltd., E; I. Pang, Alcon Research Ltd., E; A.F. Clark, Alcon Research Ltd., E.
  • Footnotes
    Support  [Supported by Alcon Research, Ltd.]
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1631. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. L. Fleenor, I.-H. Pang, A. F. Clark; Regulation of PAI-1 Protein in Human Trabecular Meshwork Cells. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1631.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : An increased level of plasminogen activator inhibitor-1 (PAI-1) appears to play a role in a variety of disease states, including cancer, obesity, and diabetes. Elevated PAI-1 levels have also been reported in the aqueous humor of glaucoma patients. Human trabecular meshwork (HTM) cells express PAI-1 protein in vitro. We investigated the signaling mechanisms involved in HTM cell production of PAI-1 protein.

Methods: : HTM cells were treated with transforming growth factor-beta2 (TGFβ2), a known stimulator of PAI-1 secretion, in the presence or absence of various signal transduction pathway inhibitors. Supernatants from the treated cultures were analyzed by ELISA for total PAI-1 protein content.

Results: : Average basal PAI-1 secretion by GTM-3 cells was 33.9 + 1.5 ng/mL/24 h (n = 233). TGFβ2 increased PAI-1 content of GTM-3 cell supernatants in a time and dose-dependent manner; a 24 h treatment with 5 ng/mL TGFβ2, enhanced PAI-1 levels by 12.02 + 0.03 fold. TGFβ2-stimulated PAI-1 levels were significantly (p < 0.05) down-regulated by inhibitors of both canonical (Smad-mediated) and non-canonical (Smad-independent) signal transduction pathways. Overall response varied from complete inhibition by agents such as SB431542 (TGFβ Type 1 receptor inhibitor; 1 µM) and rottlerin (PKCΔ inhibitor; 10 µM) to partial inhibition by SB202190 (p38 MAPK inhibitor; 100 nM), SP600125 (c-Jun N-terminal kinase inhibitor; 1 µM), and various statin agents.

Conclusions: : Modulation of PAI-1 protein expression by TGFβ2 is a complex process, involving multiple signaling pathways/mechanisms. Perturbation of one or more of these pathways may provide a novel and viable therapeutic approach to the management of glaucoma.

Keywords: trabecular meshwork • signal transduction: pharmacology/physiology • growth factors/growth factor receptors 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.